Last updated on

Journal of Clinical Oncology
Research Hotspot & Journal Scope - nivolumab


Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.4_SUPPL.129
Phase I/II study of ramucirumab plus nivolumab in patients in second-line treatment for advanced gastric adenocarcinoma (NivoRam study).

Hiroki Hara · Hirokazu Shoji · Daisuke Takahari · Taito Esaki · Nozomu Machida · Kengo Nagashima · Kazunori Aoki · Kazufumi Honda · Takahiro Miyamoto · Narikazu Boku · Ken Kato ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.7_SUPPL.388
NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02.

Arlene Odelia Siefker-Radtke · Mayer Fishman · Arjun Vasant Balar · Giovanni Grignani · Adi Diab · Jianjun Gao · Mary Tagliaferri · Alison L. Hannah · Erin E. Karski · Jonathan Zalevsky · Ute Hoch · Ahsan Naqi Rizwan · Mehmet Asim Bilen ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.8516
Ph1/2 study of Rova-T in combination with nivolumab (Nivo) ± ipilimumab (Ipi) for patients (pts) with 2L+ extensive-stage (ED) SCLC.

Jyoti Malhotra · Petros Nikolinakos · Ticiana Leal · Jonathan M. Lehman · Daniel Morgensztern · Jyoti D. Patel · John Wrangle · Giuseppe Curigliano · Eric Dansin · Laurent Greillier · Melissa L. Johnson · Neal Ready · Gilles Robinet · Satwant Lally · Shekman Wong · Emin Avsar · Ricardo Valenzuela · Charity D. Scripture · Giovanni Selvaggi · Benjamin Besse ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.8563
BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response—Preliminary results from the SCLC cohort.

Rieke Fischer · Julie George · Andreas H. Scheel · Hans Anton Schloesser · Maria J.G.T. Vehreschild · Peter Brossart · Walburga Engel-Riedel · Frank Griesinger · Christian Grohé · Karl-Otto Kambartel · Jens Kern · Barbara Hermes · Kathrin Nachtkamp · Jens Panse · Martin Sebastian · Markus Lehmann · Rainer Wiewrodt · Reinhard Büttner · Roman K. Thomas · Juergen Wolf ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.4_SUPPL.TPS179
bTMB-High Basket trial: A multicenter phase II trial of nivolumab monotherapy in patients with advanced gastrointestinal cancers with high blood tumor mutational burden (bTMB).

Yoshiaki Nakamura · Yoshito Komatsu · Ken Kato · Eiji Shinozaki · Hideaki Bando · Takeshi Kato · Tomohiro Nishina · Taito Esaki · Shogo Nomura · Gakuto Ogawa · Ayako Sugama · Miki Fukutani · Akihiro Sato · Justin I. Odegaard · Takeshi Kuwata · Kouji Matsushima · Tetsuya Nakatsura · Hiromichi Nakajima · Takayuki Yoshino ·

Medicine
PDF

Antibodies against ligands for PD-1 receptors were then developed to overcome the adverse effects of anti-PD-1 antibodies and combination of monoclonal antibodies (ipilimumab plus nivolumab) was tested to increase the response rates.

Monoclonal Antibodies for the Treatment of Melanoma: Present and Future Strategies. [10.1007/978-1-4939-8958-4_4]


It was demonstrated that nivolumab therapy for resectable NSCLC patients prior to surgery resulted in major pathological responses in 40% of the patients.

Immunological impact of surgery in NSCLC patients [10.1093/annonc/mdz258.006]


Nivolumab plus ipilimumab combined therapy is one of the promising drugs that enhance the anti- immune response in patients with advanced melanoma.

Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy [10.1159/000504019]


Five of these referred to melanoma patients who received nivolumab monotherapy or nivolumab in combination with ipilimumab.

Guillain‐Barré Syndrome Related to Nivolumab: Case Report of a Patient With Urothelial Cancer and Review of the Literature [10.1016/j.clgc.2018.11.022]


Les resultats confirment a la fois l’activite et le profil d’innocuite du nivolumab dans le cadre de la seconde et troisieme ligne dans la pratique clinique habituelle, y compris les populations de patients sous-representees dans les essais cliniques princeps.

Immunothérapie pratique, pratique de l’immunothérapie: de la prise en charge initiale au suivi [10.1016/s2096-5192(19)30158-2]



Research Hotspot

Journal of Clinical Oncology

Research Hotspot
Journal of Clinical Oncology Related Journals

Popular Journals